Novo Nordisk, a leader in breakthrough hemostasis research and treatment, today announced the appointment of Howard Levy, M.D., Ph.D., as executive director of clinical research-hemostasis in the company’s clinical development, medical, and regulatory affairs department. In this position, Dr. Levy will lead the company’s hemostasis clinical development activities in North America. Dr. Levy will replace Marcus Carr, M.D., who was promoted to vice president of Novo Nordisk Research US, the first hemostasis research facility in the United States dedicated to life-threatening bleeding.
